STABLE LIQUID INTERFERON FORMULATIONS
First Claim
1. A method of treating multiple sclerosis in a patient, comprising administering to said patient a liquid composition, wherein said liquid composition comprises:
- (i) an interferon-beta and (ii) between about 0.3% and 5% by weight of an amino acid selected from the group consisting of acidic amino acids, arginine and glycine, wherein the composition does not comprise serum albumin and;
wherein the liquid composition has not been previously lyophilized.
5 Assignments
0 Petitions
Accused Products
Abstract
Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added to provide sufficient ionic strength. The liquid composition has not been previously lyophilized or previously cavitated. The liquid is preferably contained within a vessel having at least one surface in contract with the liquid that is coated with a material inert to adsorption of interferon-beta. A kit for parenteral administration of a liquid interferon formulation and a method for stabilizing liquid interferon compositions are also described.
-
Citations
56 Claims
-
1. A method of treating multiple sclerosis in a patient, comprising administering to said patient a liquid composition, wherein said liquid composition comprises:
- (i) an interferon-beta and (ii) between about 0.3% and 5% by weight of an amino acid selected from the group consisting of acidic amino acids, arginine and glycine, wherein the composition does not comprise serum albumin and;
wherein the liquid composition has not been previously lyophilized. - View Dependent Claims (44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)
- (i) an interferon-beta and (ii) between about 0.3% and 5% by weight of an amino acid selected from the group consisting of acidic amino acids, arginine and glycine, wherein the composition does not comprise serum albumin and;
-
2-43. -43. (canceled)
Specification